Enes Emir İlErler

Enes Emir İlErler

Auto-generated profile, based on publicly available information

Enes Emir İlErler

Clinical Pharmacy Department, Faculty of Pharmacy, Istinye University , Istanbul

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
BEBüşra Ergen
Büşra Ergen
LDLütfiye Mülazımoğlu Durmuşoğlu
Lütfiye Mülazımoğlu Durmuşoğlu
TTTekin Tunçel
Tekin Tunçel
UKUmut Sabri Kasapoglu
Umut Sabri Kasapoglu
EYErdem Yalcinkaya
Erdem Yalcinkaya
MSMesut Sancar
Mesut Sancar

5 January 2026 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Verified
Journal Article
Closed access
DÜDuygu Ünder
Duygu Ünder
BÖBetül Özgan
Betül Özgan
MAMüzeyyen Aksoy
Müzeyyen Aksoy
EIEnes Emir İlErler
Enes Emir İlErler
ÖÖÖmer Faruk Özkanlı
Ömer Faruk Özkanlı
STSongul Tezcan
Songul Tezcan
Objective: The clinical pharmacy specialization program (CPSEP), initiated in 2018, aims to train expert pharmacists for clinical pharmacy services in hospitals. No study has yet evaluated medication therapy recommendations within the first "clinical pharmacy consultation system (CPCS)" integrated into Türkiye’s hospital framework. This study aims to assess the clinical pharmacy services delivered through the CPCS. Material and Method: This study was conducted on a tertiary-level hospital in Istanbul between February 2024-January 2025. The first 11 months of CPCS integration were evaluated. Result and Discussion: Sixty-nine patients were consulted, mostly adults (59.4%), primarily in hospital wards (65.2%) and intensive care units (26.1%). Common diagnoses included acute kidney injury (34.8%), infections (29.0%), and hematological malignancies (18.8%). Patients had a median of 9 medications (IQR, 8–15) and 2 comorbidities (IQR, 1–3). Common consultation reasons were adverse drug reactions (39.1%), potential drug interactions (27.5%), medication errors (14.5%), and inappropriate drug selection (5.8%). Eighty recommendations were provided, mostly regarding drug/laboratory monitoring (44.9%), dose adjustments (15.9%), and drug initiation/substitution (15.9%). Most consultations (84.1%) involved a single recommendation. These findings indicate that CPCS is actively used in drug therapy management within the national healthcare system. Although around five similar systems have been integrated in Turkish hospitals since 2023, this study presents the first published results of CPCS.

26 September 2026 in Journal Of Nephrology
Verified
Journal Article
Open access
EIEnes Emir Ilerler
Enes Emir Ilerler
BUBetul Yildiz Ustun
Betul Yildiz Ustun
MBMuhammed Yunus Bektay
Muhammed Yunus Bektay
MSMesut Sancar
Mesut Sancar
Background: Cardiac-surgery-associated acute kidney injury (CSA-AKI) is common and irreversible. Heavier early vasopressor use is linked to it; whether risk reflects achieved pressure or delivered dose is unclear. We describe these associations in two cohorts. Methods: Two cohorts were analysed separately (not pooled): primary (n=9,969, 705 CSA-AKI, 7.1%) and replication (n=3,292, 190, 5.8%). Exposure was cumulative first-24h vasopressor dose-load (norepinephrine-equivalent); achieved mean arterial pressure (MAP) is post-treatment. Outcome was creatinine/renal replacement therapy (RRT)-defined KDIGO stage 2-3 within 7 days, death competing. Results: More vasopressor accompanied lower achieved MAP (rho -0.20 and -0.59). Higher dose-load was associated with CSA-AKI (adjusted OR per SD 1.25 [95% CI 1.16-1.35] and 2.96 [2.23-3.92]), persisting with exposure and outcome windows separated (landmark 1.22 and 3.29). Risk rose as achieved MAP fell (adjusted OR per SD 0.89 and 0.55). The highest-dose, lowest-pressure group - a descriptive high-risk haemodynamic phenotype ("refractory") - carried the greatest adjusted absolute excess (6.1% [3.0-9.6] and 9.9% [3.2-17.8]). Dose-load also predicted 28-day mortality, a non-renal outcome (OR 1.47 and 2.48), supporting its interpretation primarily as a marker of illness severity rather than evidence of direct kidney toxicity. Conclusions: More vasopressor was not accompanied by higher achieved pressure; the patient whose dose climbs while pressure falls signals high kidney risk. These descriptive findings support recognising and monitoring this phenotype and enriching prospective trials; they establish no blood-pressure target (including 65 mmHg) and no case for dose reduction.

1 April 2024 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
DÜDuygu Ünder
Duygu Ünder
CECüneyd Enver
Cüneyd Enver
MDMuhammed Yasir Demi̇rCi̇
Muhammed Yasir Demi̇rCi̇
YAYunus Emre emre Ayhan
Yunus Emre emre Ayhan
BÖBetül Özgan
Betül Özgan
MSMesut Sancar
Mesut Sancar
Objectives: Drug -related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist -led medication review in hospitalized probable patients with coronavirus disease -2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in T & uuml;rkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician's acceptance rate of clinical pharmacists' recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug -related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.

4 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMüzeyyen Aksoy
Müzeyyen Aksoy
EIEnes Emir Ilerler
Enes Emir Ilerler
EYErdem Yalcinkaya
Erdem Yalcinkaya
UKUmut Sabri Kasapoglu
Umut Sabri Kasapoglu
HAHuseyin Arikan
Huseyin Arikan
MSMesut Sancar
Mesut Sancar
Sepsis and septic shock are associated with profound pathophysiological changes that alter drug pharmacokinetics, complicating optimal medication dosing in critically ill patients. Inadequate understanding of these alterations may result in inappropriate drug exposure, potentially leading to treatment failure or toxicity. This study aimed to assess healthcare professionals’ knowledge, attitudes, and behaviors regarding pharmacokinetic-guided drug dosing in sepsis and septic shock. A cross-sectional survey study was conducted among physicians and clinical pharmacists in Türkiye between September and December 2025. A structured questionnaire was developed using a modified Delphi process and assessed knowledge, attitudes, behaviors, and clinical application through a dosing scenario. A total of 203 healthcare professionals participated. The mean knowledge score was 3.67 ± 1.70 out of 7, with only 31.5% demonstrating high knowledge levels. Notable gaps were identified in areas such as anticoagulant dosing and pharmacokinetic changes during continuous renal replacement therapy. Despite these gaps, participants reported positive attitudes toward individualized dosing (mean score: 4.25 ± 0.30) and generally favorable practices (mean score: 4.00 ± 0.64). Clinical pharmacists demonstrated significantly higher knowledge scores than physicians (p < 0.001) and greater accuracy in the clinical scenario (94.1% vs. 72.8%, p = 0.008). Substantial knowledge gaps exist among healthcare professionals regarding pharmacokinetic-guided drug dosing in sepsis. The identified knowledge gaps may increase the risk of inappropriate dosing decisions, although actual prescribing behavior, drug exposure, and patient outcomes were not evaluated. Targeted educational interventions and strengthened multidisciplinary collaboration are essential to support safer and more effective medication use in the intensive care setting.